Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies

T(H)9 cells join the ever-growing list of CD4(+) T helper subsets and primarily mediate anti-parasite immune responses. We have recently demonstrated that tumor-specific T(H)9 cells induce a CCL20-CCR6-dependent regulation of DCs while stimulating CD8(+) T cell-mediated antitumor immunity. These fin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yong, Yi, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661147/
https://www.ncbi.nlm.nih.gov/pubmed/23802062
http://dx.doi.org/10.4161/onci.23084
Descripción
Sumario:T(H)9 cells join the ever-growing list of CD4(+) T helper subsets and primarily mediate anti-parasite immune responses. We have recently demonstrated that tumor-specific T(H)9 cells induce a CCL20-CCR6-dependent regulation of DCs while stimulating CD8(+) T cell-mediated antitumor immunity. These findings offer a novel immunotherapeutic strategy against cancer.

Ejemplares similares